Business · 23/10/20261 min read
Georgiamune and Menarini Group conclude an exclusive worldwide licensing and cooperation agreement for GIM-621, a first-in-class oral immunoncology drug
Summary
GIM-621 is a first-in-class immunotherapy in the form of an oral low molecular active ingredient at preclinical stage, potentially used for various solid tumors.
Original source language: PR Newswire — Global News ReleasesOpen original release →